NCT01818141View on ClinicalTrials.gov

Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin

PHASE4CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 17, 2012

Primary Completion Date

December 15, 2014

Study Completion Date

December 15, 2014

Conditions
Clostridium Difficile Infection
Interventions
DRUG

Vancomycin

Vancomycin 125mg by mouth every 6 hours for 10 days

DRUG

Fidaxomicin

Fidaxomicin 200mg by mouth every 12 hours for 10 days

Trial Locations (1)

06102

Hartford Hospital, Hartford

All Listed Sponsors
collaborator

Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

lead

Hartford Hospital

OTHER

NCT01818141 - Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin | Biotech Hunter | Biotech Hunter